论文部分内容阅读
该所承担研制的无支原体新生牛血清系列产品项目,于1995年12月已通过了杭州市科委组织的鉴定。与会专家一致认为:自该项成果在国内尚属首创,填补了国内空白,与美国Gibco公司同类血清质量相符,达到国际先进水平。” 该产品是我国“八五”、“九五”、“863.”重大科研项目开展细胞融合、淋巴细胞培养及疫苗生产等研究生产的关键材料。该项研究成果的完成,替代了该产品的进口,并满足了国内400余家科研和生产单位的迫切需要,受到了用户的一致好评,取得了良好的社会效益。
The project undertaken without Mycoplasma neonatal bovine serum products, in December 1995 has passed the identification of Hangzhou Science and Technology Commission. Experts at the meeting agreed that: Since the achievement was the first in China, it filled the gap in China and conformed to the similar serum quality of Gibco Company of the United States and reached the international advanced level. “This product is the key material for the research and production of cell fusion, lymphocyte culture and vaccine production in major research projects in China during the” Eighth Five-Year Plan “,” Ninth Five-Year Plan “and” 863. "Completion of the research results replaced the product Of imports, and to meet the domestic more than 400 research and production units in urgent need, by the user’s praise, and achieved good social benefits.